Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research
Our results support the use of telemedicine for informed consent discussions in clinical cancer research studies of biomarkers and clinical trials.
Authors
- Michael J. Morris (ORCID: https://orcid.org/0000-0002-9454-0096)
- Samuel A. Funt (ORCID: https://orcid.org/0000-0002-7235-6319)
- Michal Sternschuss (ORCID: https://orcid.org/0000-0003-2985-4483)
- Andrew Julian Vickers (ORCID: https://orcid.org/0000-0003-1525-6503)
- Emily Vertosick (ORCID: https://orcid.org/0000-0001-6948-9850)
- Peter D. Stetson (ORCID: https://orcid.org/0000-0002-8984-1302)
- Michael Lattanzi (ORCID: https://orcid.org/0000-0002-6500-4753)
- Jonathan E. Rosenberg (ORCID: https://orcid.org/0000-0003-2637-4249)
- Gregory J. Riely (ORCID: https://orcid.org/0000-0001-5357-4313)
- Gopa Iyer (ORCID: https://orcid.org/0000-0002-5093-6099)
- Ashley Marie Regazzi (ORCID: https://orcid.org/0000-0002-6019-1852)
- Michael Buckley (ORCID: https://orcid.org/0000-0001-9150-1326)
- Joseph M. Lengfellner (ORCID: https://orcid.org/0000-0002-3921-9507)
- Mia Austria (ORCID: https://orcid.org/0000-0002-7169-739X)
- David B. Solit (ORCID: https://orcid.org/0000-0002-6614-802X)
- Sené Martin
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- Texas Oncology (US)
- Rabin Medical Center (IL)
- Molecular Oncology (United States) (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1200/op-24-01041
- Primary Topic
- Patient-Provider Communication in Healthcare
- Type
- article
- Field-Weighted Citation Impact
- 0.00